Danaher/Beckman Coulter
On February 7, 2011, Danaher (NYSE: DHR) and Beckman Coulter, Inc. (NYSE: BEC) announced that they have entered into an agreement whereby Danaher will acquire Beckman for $83.50 per share in cash, or a total consideration of $6.8 billion.
Closing is expected in H111.
The transaction is structured as a tender offer for all outstanding shares of Beckman Coulter followed by a merger.
Goldman, Sachs & Co. is acting as financial advisor to Beckman Coulter in connection with the transaction.
Latham & Watkins, LLP is serving as legal counsel to Beckman Coulter in connection with the transaction.
Closing is expected in H111.
The transaction is structured as a tender offer for all outstanding shares of Beckman Coulter followed by a merger.
Goldman, Sachs & Co. is acting as financial advisor to Beckman Coulter in connection with the transaction.
Latham & Watkins, LLP is serving as legal counsel to Beckman Coulter in connection with the transaction.
View Older Stories
-
Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences
-
Beckman Coulter Announces FDA clearance of DxC 500i Clinical Analyzer, an integrated Clinical Chemistry and Immunoassay System
-
Beckman Coulter Introduces Cutting-Edge Research Use Only Assays for Neurodegenerative Disease Research
-
Beckman Coulter and Scopio Labs Add World's First Digital Bone Marrow Imaging and Analysis to Long-Term Partnership
-
Beckman Coulter's DxI 9000 Immunoassay Analyzer Honored at Premier, Inc.'s Annual Supplier Innovation Celebration
-
Danaher (DHR) Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
-
Danaher Announces Two New Centers of Innovation in Diagnostics to Transform Precision Medicine Development
-
Beckman Coulter Introduces New Integrated Chemistry and Immunoassay Analyzer
-
Danaher appoints Julie Sawyer Montgomery to Executive Vice President for Diagnostics
-
Danaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
-
Curiox Biosystems and Beckman Coulter Life Sciences Announce a Partnership Combining C-FREE™ Technology with DURA Innovations for Hands-Free Washed Sample Preparation for Flow Cytometry
-
Danaher, Jennifer Doudna, and Innovative Genomics Institute Launch Danaher-IGI Beacon for CRISPR Cures with Aim to Address Hundreds of Diseases Using Gene-editing Platform Solution
-
Beckman Coulter's DxI 9000 Immunoassay Analyzer with Increased Assay Development Sensitivity Makes First North American Appearance at 2023 AACC
-
Beckman Coulter Receives FDA Clearance for DxC 500 AU Chemistry Analyzer, Expanding Portfolio with Proven Six Sigma Performance
-
Beckman Coulter Connects Scopio Labs Digital Cell Morphology with Hematology Workcell Extending Automated Workflow
-
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer’s Disease Test Therapeutics
-
Beckman Coulter and Fujirebio Partner to Bolster Access to Patient-friendly, Blood-based Alzheimer's Disease Test
-
Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance
-
Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections
-
Beckman Coulter Acquires Artificial Intelligence Company Providing Evidence-Based Clinical Decision Support for Emergency Departments
-
Beckman Coulter Partners with Mass General and BARDA to Identify Severe Pediatric Infections in Emergency Departments
-
Beckman Coulter and Scopio Labs Partner to Accelerate Adoption of Hematology Digital Cell Morphology Platform
-
Beckman Coulter's new urinalysis solution improves laboratory workflow by significantly reducing manual reviews to 4%(1) and cutting sample processing time by up to 78%(2)
-
Demaris Mills Appointed President of IDT
-
Beckman Coulter to Distribute BNP Cardiac Assay to Customers
-
Beckman Coulter Launches First Fully Quantitative and Automated COVID-19 IgG Test to Assess Antibody Immune Response Levels
-
/C O R R E C T I O N -- Beckman Coulter Diagnostics/
-
Beckman Coulter is First Diagnostics Company to Offer Workflow Automation Specifically for Mid-volume Laboratories
-
Danaher (DHR) Announces Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA
-
Beckman Coulter's SARS-CoV-2 IgG II antibody test receives Emergency Use Authorization from the FDA
-
/C O R R E C T I O N -- Beckman Coulter Diagnostics/
-
Beckman Coulter Offers $4/High-throughput Antigen Test to Support U.S. Government Initiative to Expand COVID-19 Testing
-
Beckman Coulter brings the productivity and efficiency benefits of large volume hematology analyzers to small- and medium-sized labs
-
Beckman Coulter Launches the First High-Quality, High-Throughput COVID-19 Antigen Test Ideal for Mass Testing in the U.S. (DHR)
-
Beckman Coulter Launches the First High-Quality, High-Throughput COVID-19 Antigen Test Ideal for Mass Testing in the U.S.
-
Danaher announces leadership appointment
-
Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antibody test
-
Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries accepting CE Mark and will begin shipping to diagnostics labs
-
Beckman Coulter receives BARDA funding to validate Monocyte Distribution Width in the rapid detection of Multisystem Inflammatory Syndrome (MIS-C), a severe COVID-19 complication in Children
-
Beckman Coulter SARS-CoV-2 IgM Antibody Test Receives FDA Emergency Use Authorization
-
Beckman Coulter Completes First In A Series Of Antibody Neutralization Studies
-
Danaher (DHR) Reports FDA Emergency Use Authorization awarded to the Beckman Coulter Access IL-6 test
-
FDA Emergency Use Authorization awarded to the Beckman Coulter Access IL-6 test
-
Beckman Coulter Lauded by Frost & Sullivan for Accelerating Sepsis Detection with the DxH 690T
-
Beckman Coulter Launches SARS-CoV-2 IgM Antibody Test and will begin shipping to U.S. Diagnostics Labs
-
Study shows patients with abnormal values of Beckman Coulter's novel MDW biomarker are four- to six- times more likely to be diagnosed with (or develop) sepsis
-
Beckman Coulter's Automated Blood Banking Analyzer Receives 510(k) FDA Clearance
-
Beckman Coulter Wins SelectScience Awards for Best New Clinical Instrumentation and Customer Service of the Year
-
Beckman Coulter Receives Nine IMV ServiceTrak™ Clinical Laboratory Awards
-
Beckman Coulter, Lenco Diagnostic Laboratories deliver more than 20,000 highly accurate COVID-19 antibody tests each week to New York City; Congressman Max Rose and Brooklyn Borough President Eric Ada

